VRDN Earnings
Wednesday, May 06 2026
EPS Estimate
$-1.08
$-1.29 – $-0.94
Revenue Estimate
$0M
Current Price
$13.42
Our Position
bullish · highViridian insiders buy $40M, trial drives 13% gain
structured data
est. revisions stable
Strong insider conviction paired with a successful pivotal trial underpins potential revaluation and recovery from a 51.8% YTD decline in a volatile biotech sector.
Watch: Watch upcoming regulatory updates on elegrobart as they will confirm market access and potential revenue ramp.
Data Signal Summary
1 bullish
3 bearish
Estimates down -3%
Insider buying cluster
Put/call 1.6 (bearish skew)
Price downtrend
Key Context
Insider Activity
buying
Price Trend
downtrend
1-Month Return
-31.1%
From 52w High
-53.1%
Est. Revisions (30d)
-3.1% 0up/1dn
Analyst Target (mean)
$34 $20–$50 +150%
Options P/C Ratio
1.62
Est. Dispersion
33% 11 analysts
Insider Cluster
strong buy (officer)
Fund Convergence
moderate D.E. Shaw, Citadel
Recent Activity
insider trades
10 transactions
Other
·
BEETHAM THOMAS W (Chief Operating Officer)
·9,409 shares
Other
·
MAHONEY STEPHEN F (Chief Executive Officer)
·18,357 shares
Other
·
HARMON SETH (Chief Financial Officer)
·6,267 shares
Other
·
TOUSIGNANT JENNIFER (Officer)
·5,169 shares
Sell
·
TOUSIGNANT JENNIFER (Officer)
·2,272 shares
·$70,796
5 more
Buy
·
FAIRMOUNT FUNDS MANAGEMENT LLC
·454,545 shr
·$9,999,990
Exercise
·
FAIRMOUNT FUNDS MANAGEMENT LLC
·14,100 shr
·$166,355
Buy
·
BEETHAM THOMAS W
·5,000 shr
·$117,050
Buy
·
MAHONEY STEPHEN F
·21,400 shr
·$499,262
Buy
·
FAIRMOUNT FUNDS MANAGEMENT LLC
·1,600,000 shr
·$30,000,000
Explore more
